Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia.

No abstract is available for this paper.

• Publication year

  1994

• Venue

  Neuropeptides

• Publication date

  1994-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0143-4179(94)90131-7PMID 8208366
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients.

  1993cited by this paper
• Rapid, high-yield isolation of human chromogranin A from chromaffin granules of pheochromocytomas.

  1992cited by this paper
• Chromostatin inhibits catecholamine secretion in adrenal chromaffin cells by activating a protein phosphatase.

  1992cited by this paper
• Immunoluminometric assay of chromogranin A in serum with commercially available reagents.

  1992cited by this paper
• Immunohistochemical Study of the Distribution of Pancreastatin in Endocrine Tumors of the Pancreas and in Normal Pancreatic Tissue: Analysis of Autopsy Cases

  1991cited by this paper
• Pancreastatin-like immunoreactivity in human carcinoid disease.

  1991cited by this paper
• Bovine parathyroid glands secrete a 26-kDa N-terminal fragment of chromogranin-A which inhibits parathyroid cell secretion.

  1991cited by this paper
• The putative role of secretory protein-I/chromogranin A as a precursor for regulatory hormones.

  1990cited by this paper
• A polyclonal antiserum against chromogranin A and B--a new sensitive marker for neuroendocrine tumours.

  1990cited by this paper
• Detection of Chromogranins A and B in Endocrine Tissues with Radioactive and Biotinylated Oligonucleotide Probes

  1990cited by this paper
• Enzyme-linked immunosorbent assay for chromogranin A.

  1989cited by this paper
• Plasma pancreastatin-like immunoreactivity in various diseases.

  1989cited by this paper
• Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure.

  1989cited by this paper
• Chromogranin A and B messenger ribonucleic acids in pituitary and other normal and neoplastic human endocrine tissues.

  1989cited by this paper
• Pancreastatin Inhibits Insulin Secretion and Stimulates Glucagon Secretion in Mice

  1988cited by this paper
• The sequence of porcine chromogranin A messenger RNA demonstrates chromogranin A can serve as the precursor for the biologically active hormone, pancreastatin.

  1988cited by this paper
• Is chromogranin a prohormone?

  1987cited by this paper
• Isolation and Characterization of Chromogranins A, B, and C from Bovine Chromaffin Granules and a Rat Pheochromocytoma

  1987cited by this paper
• Secretion of chromogranin A by peptide-producing endocrine neoplasms.

  1986cited by this paper
• Immunological Characterization of Secretory Proteins of Chromaffin Granules: Chromogranins A, Chromogranins B, and Enkephalin‐Containing Peptides

  1985cited by this paper
• Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay.

  1984cited by this paper
• Human chromogranin A. Purification and characterization from catecholamine storage vesicles of human pheochromocytoma.

  1984cited by this paper
• Immunoreactive human chromogranin A in diverse polypeptide hormone producing human tumors and normal endocrine tissues.

  1983cited by this paper
• Chromogranin A: immunohistology reveals its universal occurrence in normal polypeptide hormone producing endocrine glands.

  1983cited by this paper
• Chromogranin: widespread immunoreactivity in polypeptide hormone producing tissues and in serum.

  1983cited by this paper
• Peroxidase labelled antibody and Fab conjugates with enhanced intracellular penetration.

  1971cited by this paper

• Follow-up of patients with ECL cell-derived tumours

  2016cites this paper
• Gene expression studies

  2016cites this paper
• A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.

  2014influential citation
• Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids

  2011cites this paper
• A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia

  2010cites this paper
• Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.

  2009cites this paper
• Changes in gene expression of gastric mucosa during therapeutic acid inhibition

  2008cites this paper
• Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition

  2008cites this paper
• Cromogranina A en el diagnóstico y seguimiento de los tumores endocrinos gastroenteropancreáticos

  2008cites this paper
• Processing-independent quantitation of chromogranin a in plasma from patients with neuroendocrine tumors and small-cell lung carcinomas.

  2007cites this paper
• The chromogranin-A (CgA) in prostate cancer.

  2006cites this paper
• Gene expression studies in gastrointestinal pathophysiology and neoplasia

  2006cites this paper
• Prognostic value of plasma chromogranin A levels in patients with complicated myocardial infarction.

  2006cites this paper
• One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release

  2005cites this paper
• Rebound acid hypersecretion after long‐term inhibition of gastric acid secretion

  2005cites this paper
• Accuracy and Clinical Correlates of Two Different Methods for Chromogranin A Assay in Neuroendocrine Tumors

  2004cites this paper
• Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.

  2004cites this paper
• Treatment of ECL cell carcinoids with octreotide LAR

  2004cites this paper
• The chromogranin-secretogranin family.

  2003cites this paper
• Treatment of ECL cell carcinoids with octreotide LAR.

  2003cites this paper
• Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction.

  2003cites this paper
• mechanisms of disease The Chromogranin – Secretogranin Family

  2003cites this paper
• Hypergastrinemia as a Cause of Chromogranin A Increase in Blood in Patients Suspected to Have Neuroendocrine Tumor

  2001cites this paper
• Méthodologie et utilisation du dosage de la chromogranine A en biologie clinique

  2001cites this paper
• A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours

  2001cites this paper
• Characterisation of N-terminal chromogranin A and chromogranin B in mammals by region-specific radioimmunoassays and chromatographic separation methods.

  2000cites this paper
• The chromogranins. Historical perspectives.

  2000cites this paper
• Assessment of chromogranin A using two-site immunoassay. Selection of a monoclonal antibody pair unaffected by human chromogranin A processing.

  2000cites this paper
• Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell.

  2000cites this paper
• Chromogranine A humaine: de la biochimie à la clinique

  1999cites this paper
• Library of sequence-specific radioimmunoassays for human chromogranin A.

  1999cites this paper
• A new human chromogranin A (CgA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145-245)

  1999cites this paper
• Application of region-specific immunoassay for human chromogranin A: substantial clue for detection and measurement of chromogranin A in human plasma.

  1999cites this paper
• Increased plasma pancreastatin-like levels in gestational diabetes: correlation with catecholamine levels.

  1998cites this paper
• Neuroendocrine differentiation in human gastric carcinoma

  1998cites this paper
• Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones.

  1997cites this paper
• Evidence that rat stomach ECL cells represent the main source of circulating pancreastatin.

  1997cites this paper
• Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings?

  1997influential citation
• Use of neuroendocrine serum markers in the follow‐up of patients with cancer of the prostate

  1997cites this paper
• Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors.

  1997cites this paper
• Normal pancreastatin-like and increased post-glucose insulin levels in young offspring of insulin-resistant non-obese essential hypertensive patients.

  1997cites this paper
• Marked increase in gastric acid secretory capacity after omeprazole treatment.

  1996cites this paper
• Expression of prohormone convertase, PC2, in adrenocorticotropin-producing thymic carcinoid with elevated plasma corticotropin-releasing hormone.

  1996cites this paper
• Pancreastatin secretion by pituitary adenomas and regulation of chromogranin B mRNA expression.

  1996cites this paper
• Endocrinopathy and ectopic hormones in malignancy.

  1996cites this paper
• Chromogranin A and pancreastatin-like immunoreactivity in normal pregnancies.

  1996cites this paper
• Pancreastatin: further evidence for its consideration as a regulatory peptide.

  1996cites this paper
• Increased plasma pancreastatin‐like immunoreactivity levels in non‐obese patients with essential hypertension

  1995cites this paper
• Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach.

  1995cites this paper
• Plasma pancreastatin-like immunoreactivity correlates with plasma norepinephrine levels in essential hypertension.

  1995cites this paper
• National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Neoplasms of the Dispersed Neuroendocrine System

  year unknowncites this paper